Armata Pharmaceuticals

Armata Pharmaceuticals’ stock rose sharply after the FDA granted the phage candidate AP-SA02 "Breakthrough Therapy" status for the adjuvant treatment of complicated Staphylococcus aureus bacteremia. The designation is based on phase 1b/2a data in which 100% of patients treated with AP-SA02 showed a sustained clinical response 28 days after end of therapy versus 75% in the placebo group. AP-SA02 also received Fast Track and Qualified Infectious Disease Product designations; the treatment was well tolerated without serious adverse events attributable to the product. » Więcej na de.investing.com

Armata has filed the complete phase‑3 protocol and responses to FDA feedback for the bacteriophage candidate AP‑SA02 to treat complicated S. aureus bacteremias. Four engineering runs have been completed in cGMP production in Los Angeles; production of clinical trial material and study start are planned for the second half of 2026. AP‑SA02 holds FDA designations Qualified Infectious Disease Product and Fast Track; the U.S. Department of Defense is funding development with an additional $2.5 million (total $28.7 million). Investors reacted positively, the share price rose markedly, and David House was promoted to CFO. » Więcej na de.investing.com

The FDA has granted fast-track status to Armata’s intravenous multi-phage candidate AP-SA02 for the treatment of complicated S. aureus bacteremias, enabling more frequent interaction with the agency, rolling review of approval, and potentially accelerated approval. AP-SA02 showed positive Phase 1b/2a results, and Armata plans a Phase 3 superiority study in the second half of 2026. Analysts mostly rate the stock a buy with price targets of $15 to $20, although the company was recently unprofitable and reported a loss per share of $4.80. » Więcej na de.investing.com